The biopharmaceutical industry continues to develop transformative new treatments — including innovative cell and gene therapies — that hold the potential to dramatically shift the course of public health around the globe. These sophisticated biopharmaceutical products create entirely new cold chain challenges — ones that cannot be solved with a simple retrofit of existing cold chain offerings. The fragility of these new biopharmaceutical products requires a complete rethinking of shipping and logistics strategies. The stakes couldn’t be higher. To consistently deliver products in perfect condition — and to comply with ever-increasing compliance requirements — shippers must gain more precise control of temperature, humidity, shock and vibration. Pressured by the hypercompetitive and unforgiving landscape of a $160 billion (€123,440,000,000)-and-growing market, pharmaceutical companies must achieve this consistency and control without eating into margins. And, they must retain the agility to pursue emerging markets in diverse climates worldwide. To rise to this challenge, pharmaceutical companies need a partner with the expertise to understand their offerings at a molecular level and the proven cold chain logistics experience to get it right — the first time, every time. There is simply too much riding on every shipment for patients, clinicians and pharmaceutical companies to leave cold chain to chance. A Strong Case for Rethinking Your Cold Chain Strategy CrEdoTM cargo vaccines destination: St. Petersburg, Russia External temp: -40°C INTERNAL temp: stable